Severity of SARS-Cov-2 infection and angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis
Item Type:Journal Article
Citation:Oscanoa, T. J., Vidal, X., Carvajal, A., Amado, J., Romero-Ortuno, R., Severity of SARS-Cov-2 infection and angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis, Arterial Hypertension, 2020, 24, 3, 106-114
111. AH COVID severity and ACEi ARA Oscanoa.pdf (PDF) 1.095Mb
Background: The mechanism of entry of SARS-CoV-2 into the human host cell is through the ACE2 receptor. During the pandemic, a hypothesis has been proposed that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) could be risk factors for the development of severe SARS-CoV-2 infection.The objective of the study was to conduct a meta-analysis of the association between ACEI or ARB use and SARS-CoV-2 infection severity or mortality. Data Sources: We searched PubMed, EMBASE, Google scholar and the Cochrane Database of Systematic Reviews for observational studies published between December 2019 and August 4, 2020. Study Selection: Studies were included if they contained data on ACEIor ARB use and SARS-CoV-2 infection severity or mortality. Effect statistics were pooled using random-effects models. The quality of included studies was assessed with the Newcastle–Ottawa Scale (NOS). Data extraction: Data on study design, study location, year of publication, number of participants, sex, age at baseline, outcome definition, exposure definition, effect estimates and 95% CIs. Results: Twenty-six studies (21cohort studies and 5 case-control studies) were identified for inclusion,combining to a total sample of 361467 participants. Mean age was 61.48 (SD8.26) years and 51.63 % were men. The mean NOS score of included studies was 7.85 (range: 7–9). Results suggested that ACEI or ARB use did not increase the risk of severe disease or mortality from SARS-CoV-2 infection (OR=0.88, 95% CI:0.75–1.02, p>0.05). Conclusions: At present, the evidence available does not support the hypothesis of increased SARS-CoV-2 risk with ACEI or ARB drugs.
Author: Romero-Ortuno, Roman
Other Titles:Severity of SARS-COV-2 infection and renin–angiotensin system blockers: a metanalysis
Type of material:Journal Article
Series/Report no:Arterial Hypertension;
Availability:Full text available
Keywords:SARS-CoV-2, COVID-19, Angiotensin II receptor blockers, Angiotensin-converting enzyme inhibitors, Renin–Angiotensin System (RAS)
Showing items related by title, author, creator and subject.
Effect of Angiotensin II and Small GTPase Ras Signaling Pathway Inhibition on Early Renal Changes in a Murine Model of Obstructive Nephropathy DOCHERTY, NEIL (2014)Tubulointerstitial fibrosis is a major feature of chronic kidney disease. Unilateral ureteral obstruction (UUO) in rodents leads to the development of renal tubulointerstitial fibrosis consistent with histopathological ...
Lack of association between angiotensin-converting enzyme genotype and muscle strength in Peruvian older people Romero-Ortuno, Roman; Oscanoa, T.J.; Cieza, E.C.; Lizaraso-Soto, F.A.; Guevara, M.L.; Fujita, R.M.; Parodi, J.F.; Runzer-Colmenares, F.M. (2020)Aging can be associated with decreasing muscle strength, and related factors are comorbidities, sex, physical activity, and possibly genetic factors. Among genetic factors the renin-angiotensin system is of interest, but ...
Angiotensin-Converting Enzyme (ACE) genetic variation and longevity in Peruvian older people: a cross-sectional study Romero-Ortuno, Roman; Oscanoa, Teodoro J.; Cieza, Edwin C.; Lizaraso-Soto, Frank A.; Guevara, María L.; Fujita, Ricardo M. (2020)Background: Some studies have suggested that the insertion(I)/deletion(D) polymorphism of the Angiotensin-Converting Enzyme (ACE) gene may be associated with human longevity, especially in centenarians. However, this ...